Additionally, CD30 is overexpressed in up to 80% of primary mediastinal large B cell lymphomas (PMBCL), 70% of post-transplant lymphoproliferative disorders (PTLD), and primary effusion lymphomas (PEL), suggesting a potential role for targeted therapy in these settings [103,104,105]. The gene discussed is TNFRSF8; the disease is primary effusion lymphoma.